Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): September 27, 2023
PhaseBio Pharmaceuticals, Inc.
(Exact name of registrant as specified in its Charter)
(State or Other Jurisdiction of
 File Number)
(IRS Employer
Identification No.)

3500 S. Dupont Highway
Dover, Delaware 19901
(Address including zip code of principal executive offices)

(610) 981-6500
(Registrant’s Telephone Number, Including Area Code)

Not Applicable
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):
    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act.
Title of each class
Trading Symbol(s)
Name of exchange on which registered
Common Stock, par value $0.001 per sharePHASQ*

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company  

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  

*On November 3, 2022, the issuer’s common stock was suspended from trading on The Nasdaq Stock Market LLC (“Nasdaq”). Effective November 4, 2022, trades in the issuer’s common stock began being quoted on the OTC Pink Marketplace under the symbol “PHASQ.” On December 21, 2022, Nasdaq filed a Form 25 to delist the issuer’s common stock and to remove it from registration under Section 12(b) of the Securities Exchange Act of 1934, as amended.

Item 5.02
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On September 27, 2023, Caroline Loewy resigned as a member of the board of directors of PhaseBio Pharmaceuticals, Inc. (the “Company”). Her resignation was not the result of any disagreement with the Company on any matter relating to the Company’s operations, policies or practices.

Exhibit No. Description
104Cover page interactive data file (formatted as Inline XBRL).

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

PhaseBio Pharmaceuticals, Inc.
Dated: October 3, 2023By:/s/ Jonathan P. Mow
Jonathan P. Mow
Chief Executive Officer

Sep. 27, 2023
Cover [Abstract]  
Document Type 8-K
Document Period End Date Sep. 27, 2023
Entity Registrant Name PhaseBio Pharmaceuticals, Inc.
Entity Incorporation, State or Country Code DE
Entity File Number 001-38697
Entity Tax Identification Number 03-0375697
Entity Address, Address Line One 3500 S. Dupont Highway
Entity Address, City or Town Dover
Entity Address, State or Province DE
Entity Address, Postal Zip Code 19901
City Area Code 610
Local Phone Number 981-6500
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, par value $0.001 per share
Trading Symbol PHASQ
Security Exchange Name NONE
Entity Emerging Growth Company true
Entity Ex Transition Period true
Amendment Flag false
Entity Central Index Key 0001169245

PhaseBio Pharmaceuticals (CE) (USOTC:PHASQ)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more PhaseBio Pharmaceuticals (CE) Charts.
PhaseBio Pharmaceuticals (CE) (USOTC:PHASQ)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more PhaseBio Pharmaceuticals (CE) Charts.